Loading…
AstraZeneca Pharma India (ASTRAZEN)₹6,515+0.54%Pharmaceuticals
In the Jun 2026 quarter (standalone), AstraZeneca Pharma India reported sales of ₹684 Cr, up 29.8% from Jun 2025, and net profit of ₹37.88 Cr, down 32.2% year on year. For the year to Mar 2026, sales were ₹2,281 Cr and net profit ₹187 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 312 | 306 | 384 | 389 | 409 | 441 | 481 | 527 | 560 | 614 | 580 | 684 |
| Expenses | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 |
| Operating Profit | 53.05 | 15.02 | 49.06 | 38.07 | 53.10 | 77.14 | 86.17 | 81.13 | 75.11 | 45.10 | 61.13 | 49.11 |
| OPM % | 16.9% | 4.9% | 13.0% | 10.0% | 12.9% | 16.9% | 17.9% | 15.0% | 13.0% | 7.0% | 11.0% | 7.0% |
| Other Income | 24.99 | 9.99 | 8.99 | −49.01 | 7.99 | −25.99 | 9.99 | 10.99 | 0.99 | 6.99 | 4.99 | 8.99 |
| Interest | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 1.01 | 1.01 | 1.99 | 1.99 |
| Depreciation | 3.99 | 3.99 | 3.99 | 3.99 | 8.99 | 8.99 | 17.99 | 16.99 | 3.01 | 3.99 | 5.99 | 5.01 |
| Profit before tax | 72.75 | 19.94 | 53.81 | −14.96 | 50.86 | 41.88 | 77.72 | 74.75 | 72.81 | 46.89 | 57.86 | 50.82 |
| Tax % | 29.0% | 23.0% | 27.1% | −22.0% | 25.0% | 27.0% | 26.0% | 25.0% | 26.0% | 30.1% | 23.0% | 25.1% |
| Exceptional items | 11.64 | 0.00 | 0.00 | −46.76 | 0.00 | −23.81 | −4.01 | −0.24 | −3.90 | 1.03 | −0.80 | −0.17 |
| Net Profit | 51.82 | 15.94 | 38.89 | −11.97 | 37.87 | 30.92 | 57.85 | 55.84 | 53.80 | 32.91 | 44.87 | 37.88 |
| EPS (Rs) | 20.92 | 6.31 | 15.76 | −4.71 | 15.34 | 12.31 | 23.28 | 22.31 | 21.65 | 13.02 | 17.93 | 15.15 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 565 | 545 | 572 | 730 | 834 | 816 | 807 | 1,005 | 1,298 | 1,720 | 2,281 | 2,438 |
| Expenses | 547 | 506 | 524 | 657 | 710 | 677 | 718 | 837 | 1,110 | 1,462 | 2,012 | 2,202 |
| Operating Profit | 16.02 | 37.04 | 46.08 | 71.08 | 121 | 135 | 86.15 | 165 | 184 | 255 | 263 | 230 |
| OPM % | 2.9% | 6.9% | 8.0% | 10.0% | 15.0% | 17.0% | 11.0% | 15.9% | 14.0% | 14.9% | 12.0% | 9.5% |
| Other Income | 6.99 | 13.99 | 12.01 | 15.99 | 12.99 | 12.99 | 14.99 | −14.01 | 50.97 | −55.96 | 22.99 | 21.96 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 1.01 | 0.99 | 0.99 | 3.99 | 6.00 |
| Depreciation | 16.99 | 16.01 | 14.99 | 15.01 | 18.98 | 20.01 | 17.01 | 15.99 | 14.99 | 39.98 | 28.98 | 18.00 |
| Profit before tax | 5.98 | 35.90 | 43.88 | 72.82 | 114 | 127 | 82.81 | 134 | 219 | 155 | 251 | 228 |
| Tax % | 9.0% | 44.0% | 41.1% | 25.0% | 37.1% | 27.1% | 26.1% | 26.0% | 26.1% | 26.0% | 26.0% | — |
| Exceptional items | 0.00 | 3.99 | 0.00 | 0.00 | 0.00 | 1.99 | 1.99 | −26.97 | 11.99 | −58.91 | −3.99 | −3.84 |
| Net Profit | 4.98 | 19.93 | 25.94 | 53.85 | 71.79 | 92.73 | 61.80 | 98.68 | 162 | 116 | 187 | 169 |
| EPS (Rs) | 2.09 | 8.01 | 10.34 | 21.74 | 28.83 | 37.24 | 24.59 | 39.63 | 64.46 | 46.26 | 74.91 | 67.75 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 3.0% | 5.0% | 41.0% | 40.1% | 37.0% | 69.1% | 48.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 |
| Reserves | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 706 | 765 | 868 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.96 | 11.96 | 8.97 | 6.98 | 4.98 | 35.90 | 111 |
| Other Liabilities | 261 | 247 | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 713 | 1,006 |
| Total Liabilities | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,077 | 1,519 | 1,988 |
| Fixed Assets | 101 | 96.87 | 86.86 | 74.85 | 74.95 | 71.89 | 80.86 | 73.88 | 68.94 | 66.87 | 63.94 | 117 |
| CWIP | 12.02 | 6.01 | 5.01 | 4.01 | 7.01 | 24.01 | 4.01 | 2.01 | 1.01 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,455 | 1,871 |
| Inventories | 85.75 | 76.81 | 57.84 | 113 | 118 | 165 | 160 | 140 | 189 | 227 | 547 | 1,025 |
| Trade receivables | 43.01 | 82.94 | 42.99 | 55.02 | 80.01 | 82.99 | 85.02 | 85.97 | 108 | 153 | 185 | 214 |
| Cash & equivalents | 25.08 | 77.29 | 116 | 126 | 174 | 254 | 353 | 450 | 501 | 508 | 539 | 451 |
| Total Assets | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,077 | 1,519 | 1,988 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −45.79 | 56.75 | 37.84 | 8.96 | 54.80 | 86.60 | 105 | 101 | 57.78 | 27.87 | 64.71 | −14.94 |
| Cash from investing activity | −18.97 | −3.99 | 0.00 | −8.99 | 3.99 | −171 | 173 | 4.99 | 17.97 | 21.97 | 30.93 | 18.96 |
| Cash from financing activity | 0.00 | −1.01 | 0.00 | 0.00 | 0.00 | −6.02 | −9.03 | −9.03 | −24.07 | −44.14 | −66.19 | −92.26 |
| Net cash flow | −63.81 | 52.81 | 37.88 | −0.99 | 58.76 | −89.72 | 268 | 95.72 | 51.81 | 4.98 | 30.87 | −87.70 |
| Capex | 23.78 | 9.03 | 5.64 | 6.27 | 18.66 | 14.21 | 7.70 | 9.60 | 8.50 | 10.74 | 1.74 | 3.60 |
| Free cash flow | −68.90 | 47.94 | 32.96 | 2.99 | 36.97 | 73.89 | 98.86 | 93.89 | 52.96 | 17.98 | 63.89 | −17.97 |
| CFO / OP % | 393.1% | 365.1% | 133.0% | 28.1% | 126.1% | 100.1% | 101.1% | 146.0% | 60.1% | 46.1% | 51.0% | 26.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 30 | 54 | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 | 39 | 34 |
| Inventory days | 156 | 140 | 120 | 228 | 185 | 196 | 197 | 163 | 192 | 139 | 207 | 271 |
| Days payable | 202 | 173 | 183 | 256 | 265 | 250 | 220 | 222 | 230 | 120 | 172 | 206 |
| Cash conversion cycle | −16 | 21 | −34 | 7 | −39 | −17 | 15 | −20 | 1 | 62 | 74 | 99 |
| Working capital days | −14 | −27 | −35 | −7 | −13 | −15 | −16 | −33 | −17 | 21 | 23 | 51 |
| ROCE % | −13.0% | 4.0% | 15.0% | 19.0% | 27.0% | 34.0% | 30.0% | 16.0% | 31.0% | 31.0% | 33.0% | 29.0% |
For the Jun 2026 quarter, AstraZeneca Pharma India reported sales of ₹684 Cr, up 29.8% year on year and net profit of ₹37.88 Cr, down 32.2% year on year. The operating margin was 7.0%.
AstraZeneca Pharma India's sales for the year to Mar 2026 were ₹2,281 Cr; over the last twelve months they were ₹2,438 Cr.
Net profit for the year to Mar 2026 was ₹187 Cr, and ₹169 Cr over the last twelve months. Earnings per share over the same trailing period were ₹67.75.
AstraZeneca Pharma India reported borrowings of ₹111 Cr at Mar 2026, against cash and equivalents of ₹451 Cr.
Cash from operations was −₹14.94 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹17.97 Cr.